Page 6 - Aytu Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated  Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating  Neos Therapeutics, Inc. ("NEOS" or the "Company") ( ) relating to its proposed merger with Aytu BioScience, Inc. Under the terms of the agreement, NEOS shareholders will receive 0.1088 shares of Aytu per share they own. The investigation focuses on...

Share: Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs. Osmotica Pharmaceuticals shares traded up 9.18% to $5.59. The stock has a 52-week high of $9.67 and a 52-week low of $2.81. Myova...

Share this article Share this article ResearchAndMarkets.com's offering. Global Gynecology Partnering 2010-2020: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes read...

(2) ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriter's option to purchase an additional 625,000 shares of common stock, at a price to the public of $6.00 per share. H.C. Wainwright & Co. acted as the sole book-running manager for...

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors...